Plain-English translation of NCT06430658 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a newer type of immunotherapy drug called tislelizumab to standard cancer treatment can help shrink hard-to-treat esophageal tumors enough to make surgery possible. The study compares three different ways of combining chemotherapy, radiation, and the medication to find the best approach for patients whose cancer is considered borderline unresectable.
Esophageal cancer that cannot be surgically removed has very poor outcomes. Recent research has shown that adding this medication to standard treatment may help more patients become eligible for surgery, which could give them better chances of survival.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of three treatment approaches: radiation with chemotherapy followed by the medication, the medication with chemotherapy followed by radiation, or radiation with chemotherapy alone. Most participants will receive about 5–6 weeks of treatment, and then your doctors will evaluate whether the tumor has shrunk enough for surgery. If surgery is possible, you will have an operation to remove the treated tumor. If surgery is not possible, you will continue on the medication as maintenance therapy. Your doctors will closely monitor you throughout treatment and for one year afterward to track how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China